Aroa Biosurgery Reports Strong FY25 Results and Positive Outlook for FY26

Aroa Biosurgery Ltd ( (AU:ARX) ) has issued an announcement.

Aroa Biosurgery Limited reported strong financial results for FY25, with a total revenue of NZ$84.7 million, marking a 23% growth from the previous year. The company achieved a positive operating cash flow and a significant improvement in EBITDA, reflecting robust sales of its Myriad and OviTex products. Looking ahead to FY26, Aroa anticipates continued revenue growth driven by Myriad sales and strategic investments in sales productivity and new product development. The company maintains a strong cash position with no debt, positioning it well for future growth.

The most recent analyst rating on (AU:ARX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on Aroa Biosurgery Ltd stock, see the AU:ARX Stock Forecast page.

More about Aroa Biosurgery Ltd

Aroa Biosurgery Limited is a company specializing in soft tissue regeneration. It offers products such as Myriad, OviTex, and Endoform, focusing on enhancing healing in complex wounds and soft tissue reconstruction.

Average Trading Volume: 321,137

Technical Sentiment Signal: Sell

Current Market Cap: A$160.4M

Learn more about ARX stock on TipRanks’ Stock Analysis page.